Results 161 to 170 of about 6,870,828 (229)

Executive function and soluble urokinase-type plasminogen activator receptor (suPAR): a longitudinal study of midlife adults. [PDF]

Brain Behav Immun
Shell A, Vize C, Gianaros P, Rasmussen LJH, Marsland AL.   +4 more
europepmc   +1 more source

Urokinase-Type Plasminogen Activator Receptor (uPAR) Cooperates with Mutated KRAS in Regulating Cellular Plasticity and Gemcitabine Response in Pancreatic Adenocarcinomas. [PDF]

Cancers (Basel), 2023
Peng L, Li Y, Yao S, Gaedcke J, Baart VM, Sier CFM, Neesse A, Ellenrieder V, Bohnenberger H, Fuchs F, Kitz J, Ströbel P, Küffer S.   +12 more
europepmc   +1 more source

Interactive Effects of IL-1β and TGF-β on Urokinase-Type Plasminogen Activator and α-Smooth Muscle Actin Expression by Corneal Fibroblasts. [PDF]

Invest Ophthalmol Vis Sci
Sugioka K, Nishida T, Yunoki M, Mukai N, Murakami J, Kusaka S.   +5 more
europepmc   +1 more source

Urokinase-Type Plasminogen Activator Receptor (uPAR) Expression and [⁶⁴Cu]Cu-DOTA-AE105 uPAR-PET/CT in Patient-Derived Xenograft Models of Oral Squamous Cell Carcinoma. [PDF]

Mol Imaging Biol, 2023
Lawaetz M, Binderup T, Christensen A, Juhl K, Lelkaitis G, Lykke E, Knudsen L, von Buchwald C, Kjaer A.   +8 more
europepmc   +1 more source

Remodeling the sarcoma microenvironment by simultaneous targeting of urokinase-type plasminogen activator receptors and epidermal growth factor receptors to promote antitumor activity. [PDF]

J Pharmacol Exp Ther
Schulte AJ, Lewellen M, Durose W, Nolan E, Taghizadeh L, Todhunter D, Bush C, Lang HP, Brown ME, DePauw TA, Makielski KM, Kim JH, Burt LE, Overn P, Forster CL, Seelig DM, O'Sullivan MG, Weigel BJ, Murugan P, Cutter GR, Lund TC, Vallera DA, Modiano JF.   +22 more
europepmc   +1 more source

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) and Growth Differentiation Factor-15 (GDF-15) Levels Are Significantly Associated with Endothelial Injury Indices in Adult Allogeneic Hematopoietic Cell Transplantation Recipients. [PDF]

Int J Mol Sci, 2023
Gavriilaki E, Bousiou Z, Batsis I, Vardi A, Mallouri D, Koravou EE, Konstantinidou G, Spyridis N, Karavalakis G, Noli F, Patriarcheas V, Masmanidou M, Touloumenidou T, Papalexandri A, Poziopoulos C, Yannaki E, Sakellari I, Politou M, Papassotiriou I.   +18 more
europepmc   +1 more source

Urokinase-type plasminogen activator deficiency enhances CD8⁺ T cell infiltration and anti-PD-1 therapy efficacy in prostate cancer. [PDF]

Front Immunol
Li X, Zhang X, Fu X, Wu H, Ye X, Huang X, Cui Y, Qian CN, Lu Y, Zhang J.   +9 more
europepmc   +1 more source

Author Correction: Urokinase-type plasminogen activator receptor (uPAR) assessed by liquid biopsies and PET/CT for prognostication in head and neck cancer patients. [PDF]

Sci Rep, 2023
Risør LM, Binderup T, Fosbøl MØ, Andersen KF, Loft A, Friborg J, Kjaer A.   +6 more
europepmc   +1 more source

Serum Soluble Urokinase-Type Plasminogen Activator Receptor: A Promising Biomarker for Stable Chronic Obstructive Pulmonary Disease Patients. [PDF]

Cureus
D R, Johnson P, Das S, Gr S.
europepmc   +1 more source

Soluble Urokinase-Type Plasminogen Activator Receptor and Inflammatory Biomarker Response with Prognostic Significance after Acute Neuronal Injury - a Prospective Cohort Study. [PDF]

Inflammation
Sajanti A, Hellström S, Bennett C, Srinath A, Jhaveri A, Cao Y, Takala R, Frantzén J, Koskimäki F, Falter J, Lyne SB, Rantamäki T, Posti JP, Roine S, Jänkälä M, Puolitaival J, Kolehmainen S, Girard R, Rahi M, Rinne J, Castrén E, Koskimäki J.   +21 more
europepmc   +1 more source